Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Addition of panitumumab can lead to an increased survival in colorectal cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.04.10
Views: 9077
Rating:

Prof Salvatore Siena - Niguarda Ca' Granda Hospital, Milan

The addition of panitumumab to standard colorectal cancer chemotherapy (oxaliplatin, leucovorin 5-and fluorouracil [5-FU]) leads to an increased survival of three months in some patients but can be detrimental to those who have a KRAS gene mutation.

Prof. Siena explains the side effects associated with this treatment but patients should be reassured that the side effects are only seen in patients who are seeing an improvement thanks to the treatment.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation